Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported Operating Income of $98.35 million for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $98.35M | +116.4% |
| 2024 | -$601.08M | -193.2% |
| 2023 | -$205.00M | -14.8% |
| 2022 | -$178.51M | -19.8% |
| 2021 | -$149.04M | -60.0% |
| 2020 | -$93.16M | -252.2% |
| 2019 | $61.19M | +209.4% |
| 2018 | -$55.94M | -51.2% |
| 2017 | -$37.00M | +54.7% |
| 2016 | -$81.74M | +14.8% |
| 2015 | -$95.97M | -80.1% |
| 2014 | -$53.28M | -116.7% |
| 2013 | -$24.59M | -16.6% |
| 2012 | -$21.09M | -114.5% |
| 2011 | -$9.83M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $40.81M | +125.3% | +124.7% |
| June 30, 2025 | -$165.55M | +6.0% | -143.4% |
| March 31, 2025 | $381.20M | +402.1% | +336.2% |
| December 31, 2024 | -$161.41M | -18.2% | +8.4% |
| June 30, 2024 | -$176.14M | -71.5% | -39.6% |
| March 31, 2024 | -$126.19M | -362.0% | +7.6% |
| December 31, 2023 | -$136.54M | -224.1% | -33.0% |
| June 30, 2023 | -$102.70M | -40.9% | -313.2% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +116.4% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, ARROWHEAD PHARMACEUTICALS, INC.’s operating income has grown by 1100.4% (from -$9.83 million to $98.35 million).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: